Bayer and German life science company Evotec have announced a strategic shift in their collaboration to focus on the development of innovative precision treatments for cardiovascular diseases (CVDs).
The deal will focus on detecting and establishing new targets to create a portfolio of precision cardiology therapeutics.
Go deeper with GlobalData
The disease-modelling capabilities of Evotec, which involve human induced pluripotent stem cells (iPSCs), will be used to develop new therapies.
iPSCs are instrumental in uncovering new disease mechanisms and pathways that can lead to the discovery of treatments.
Both Bayer and Evotec will contribute drug targets to the deal, along with high-quality technology platforms.
These resources will support the development of innovative treatment options for patients with cardiovascular conditions.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe companies have agreed to share responsibilities during the pre-clinical potential clinical candidates’ development.
Once a candidate reaches the clinical development stage, Bayer will take the lead on further development and commercialisation.
Bayer Pharmaceuticals division research and development head Dr Christian Rommel stated: “The refocused collaboration will leverage Evotec’s industrialised iPSC-based disease-modelling platform and Bayer’s leadership in cardiology to advance a portfolio of innovative therapies for cardiovascular diseases with high unmet medical need.
“This complements our focus on disease areas where we can truly improve the standard of care by delivering superior therapeutic solutions to patients in need.”
Both Bayer and Evotec did not disclose the financial terms of the agreement.
Evotec chief scientific officer Dr Cord Dohrmann stated: “Our approach is based on highly validated disease models to identify novel targets and profile drug candidates more comprehensively for their efficacy and safety.
“Intervening with these disease-associated mechanisms more comprehensively will enable the development of more effective, disease-modifying therapies with higher relevance for CVD to respond to the substantial unmet need associated with cardiovascular diseases.”
Last month, Bayer partnered with Google Cloud to expedite the development of AI-powered solutions for radiologists.
